CBS NEWS – 60 MINUTES
World-renowned geneticist Professor George Church’s lab at Harvard Medical School is working to make humans immune to all viruses, eliminate genetic diseases and reverse the aging process. He has formed over 35 companies and his lab has over 100 researchers.
VCapital hosted George and his wife, molecular biologist Professor Ting Wu last July when they spoke to a large group of our investors about the human genome (which many consider the most important key to the future of medicine), anti-aging, the use of DNA for massive data storage, and a number of startups that have emerged from their labs.
With healthcare accounting for a 17% and still growing share of the U.S. economy, George’s and Ting’s work sits prominently on the VCapital radar screen for future investment opportunities.
CBS’s 60 Minutes recently reported on how close the geneticist’s team is to a breakthrough. Watch now.
We welcome a conversation with you about the #futureofmedicine.
Event December 5, 2019
Rarely do all the stars in the venture capital universe align perfectly to offer the opportunity for potentially extraordinary returns. Intensity Therapeutics is that rarity. VCapital has been excited about Intensity Therapeutics’ mission to cure cancer since meeting CEO Lew Bender about five years ago. We learned then about the remarkable results achieved by Intensity’s lead investigational product. These remarkable results caught the attention of the National Cancer Institute, which replicated Bender’s study . . . with even better results!
Learn More about Intensity Therapeutics:
VCapital’s Our Take Report
Intensity Therapeutics’ presentation slides
Intensity Therapeutics’ Third Quarter Letter to Investors
Press Release Business Wire:Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda
Forbes November 23, 2019: Lewis Bender Started A Company to Cure Cancer
Click here to secure your seat for the face-to-face presentation.
Details about investing in Intensity Therapeutics Series C
Event November 18, 2019
Join VCapital to learn how this Augmented Reality product revolutionizes surgical procedures, making them faster and more accurate for better patient experiences.
Learn more about SentiAR:
- VCapital’s Our Take Report
- VCapital’s Opportunity Overview
- SentiAR’s presentation slides
- SentiAR’s website
Monday, November 18, 2019
University Club of Chicago 76 E. Monroe Street Chicago, IL 60603
(Valet parking validation available at registration)
4:30 pm: Registration & Refreshments
5:00 pm: SentiAR Presentation
6:00 pm: Interactive Q&A
Click here to secure your seat for the face-to-face presentation
Details about investing in SentiAR
For more information please contact:
Business Wire, October 31, 2019
“Bringing INT230-6 into human testing in combination with Keytruda is a major milestone for Intensity Therapeutics,” commented Lewis H. Bender, President and Chief Executive Officer of Intensity Therapeutics. “Our preclinical and clinical data to date have already demonstrated good safety for INT230-6 as a single agent, with evidence of patient benefit and immune activation in highly refractory cancer patients. We believe the immune activation potential of INT230-6 can be increased when combined with Keytruda, and are excited to have initiated human testing of the combination.”
Read the full press release here.
Event July 17, 2019
Please join the VCapital team, fellow investors and special guests from the greater Chicago area entrepreneurial and deal-making community for an end-of-the-work-day social get-together on Wednesday, July 17th, from 4:30 to 6:30pm, at the JW Marriott at 151 West Adams, Chicago, IL 60603.
The event highlight will be two keynote speakers, Harvard Medical School’s world-renowned geneticist Professor George Church and molecular biologist Professor Ting Wu.
For more information and to register CLICK HERE
Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium
Press Release, May 14, 2019
Lewis H. Bender, President and CEO of Intensity Therapeutics, Inc., will present a poster on the preclinical and early Phase 1/2 data of its lead product candidate, INT230-6, at The New York Academy of Sciences’ Frontiers in Cancer Immunotherapy Symposium being held May 14-15, 2019 in New York, NY at 7 World Trade Tower 40th Floor.
Press Release, February 27, 2019
Sixteen independent, primarily Midwest-based venture capital firms have established a consortium to serve Midwest-based start-ups’ funding needs as well as investors seeking the Midwest’s demonstrated exceptional venture capital returns. The consortium, with a combined $2+ billion in cash available for investment, is expected to accelerate Midwest venture capital activity by establishing a virtual one-stop venture capital shop for aspiring entrepreneurs.
Crains - September 28, 2018
Xaptum, founded by a UIC bioengineer, is tackling security for smartphones, sensors and other devices.
Rohit Pasam has been working on a way to make the internet of things safer, and he’s got another $3.1 million to do it.
His startup, Xaptum, has built a secure cloud that would keep devices, such as sensors and smartphones, from being hacked or being used to break into the closed networks to which they’re connected via the internet. VCapital, a venture fund operated by Len Batterson, led
the round. Other investors include Illinois Ventures, as well as Purple Arch Ventures, Loud Capital, Hyde Park Angels and former U.S. Robotics executives Casey Cowell and Michael Seedman
Crunchbase - May 21, 2018
Access to talented folks and smart capital certainly makes the process of starting up a company easier, and it may increase the likelihood that a startup will survive long enough to raise some money and build a sustainable business. But does location have any bearing on the other end of the startup lifecycle, when founder and investor equity is looking for an exit by way of an initial public offering (IPO) or acquisition?
Crunchbase analyzes startup exit performance by region, and the Midwest comes out on top in terms of multiples on invested capital (MOICs) over time.
Camras Vision Announces Completion of $5.7M Financing for Novel Glaucoma Device for Treatment of Refractory Glaucoma
Research Triangle Park, NC - April 9, 2018
Camras Vision has closed on $5.7M in equity funding in its Series A round led by VCapital, InFocus Capital Partners and Triangle Venture Alliance. The funding round also includes returning Series Seed investors Triangle Angel Partners, IMAF Coastal Plain, and Pilot Mountain Ventures as well as additional new angel investors. These funds will be used to support four clinical trials globally, including a pilot study in the United States, to study the efficacy of the Camras device for the treatment of refractory glaucoma.
Chicago - October 10, 2017
Len Batterson, a veteran venture capitalist and entrepreneur, and Chris
Gladwin, founder of Cleversafe (sold to INM for $1.4B) and current CEO of Ocient will speak about venture capitalism and entrepreneurship at the world’s first service club, Rotary One.
Zacks Investment Awareness - September 26, 2017
Ryan Kole discusses VCapital’s latest opportunities and investment strategy for emerging med tech and bio tech with Terry on ZIA TV.
Westport, CT - June 15, 2017
Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338.
Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial
Westport, CT - May 30, 2017
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the first patient successfully received treatment with the Company’s lead product, INT230-6, as part of a Phase 1/2 international clinical study. Initiation of the study followed acceptance of an investigational new drug (IND) submission by the US Food and Drug Administration’s Division of Oncology Products 1 (DOP1) and receipt from Health Canada of a No Objection Letter following submission of a clinical trial application (CTA). The clinical trial, IT-01 (NCT#03058289), entitled A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers, aims to enroll approximately 60 patients with several different types of advanced solid tumors.
Westport, CT - June 28, 2016
Intensity Therapeutics, Inc. raises $10 million in its Series A round to fund Phase I/II human clinical trials for its novel cancer treatment; adds two board members.
Westport, CT - June 2, 2016
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office issued the Company US Patent 9,351,997, which protects Intensity’s lead product INT230-6.
Intensity Therapeutics Reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation
Westport, CT - Business Wire - April 19, 2016
Chief Medical Officer Dr. Ian B Walters presents the mechanism of action of Intensity Therapeutics products and other data in a poster session at the American Academy of Cancer Research (AACR) meeting today, showing that INT230-6 induces significant cancer cell death in the tumor microenvironment. Thereafter, eradication of the tumor by INT230-6 requires T lymphocytes and leads to a potent and durable systemic anti-cancer T-cell-dependent immunity against the tumor.
By John Pletz, Crain's Chicago Business, April 9, 2016
Cleversafe raised $100 million, mostly from Chicago investors, including those participating in Batterson Venture Capital’s Series A investment. Chris Gladwin estimates the sale of Cleversafe created about 80 millionaires.
News Release, March 8, 2016
Intensity Therapeutics has been selected to present at the 23rd annual Future Leaders in the Biotech Industry conference hosted by BioCentury. CEO Lewis Bender will present an update on the Company and the development status of INT230-6, an immune cell-activating, anti-cancer drug candidate.
News Release, March 3, 2016
Pre-clinical research from Intensity and its collaborators at the National Cancer Institute
(NCI) were selected for oral presentation at two important upcoming congresses.
News Release, Nov. 6, 2015
IBM completes the acquisition of Cleversafe. Batterson Venture Capital was an early stage (Series A) investor in the company.
Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists
News Release, Oct. 22, 2015
Douglas Hanahan, Riccardo Lencioni and Mario Sznol join Intensity Therapeutics’ newly formed Scientific Advisory Board (SAB). These world-renowned scientists and physicians will provide research and development guidance on Intensity’s proprietary products and technology. The SAB members span a broad range of expertise relevant to Intensity’s approach including: immuno-oncology, clinical trial design, interventional oncology, tumor imaging, tumor microenvironment, cell regulation and cancer vaccination.
News Release Issued by IBM, Oct 5, 2015
IBM has entered into a definitive agreement to acquire Cleversafe, Inc. Batterson Venture Capital was an early stage (Series A) investor in the company.
by John Peltz, Crain's Chicago Business, 18 Sept 2015
At the Illinois Technology Association’s CityLights Awards honoring 8 Chicago companies, technologists and entrepreneurs, CEO of the year was awarded to John A. Morris of Cleversafe. ITA is a trade association for growth-stage tech firms.
by John Pletz, Crain's Chicago Business, 21 July 2015
VCapital is raising money online to help Intensity Therapeutics, Inc advance its cancer-reversing technology to human trials.
by Steve Hendershot, Crain's Chicago Business, 14 July 2015
Meet Cleversafe’s Jason Resch, the kind of man you build a company around, in this brief profile leading up to Crain’s full reveal of Chicago’s TECH 50.
iRODS Consortium, 12 May 2015
Cleversafe, the market share leader in web-scale data storage, will become the ninth member of the iRODS Consortium, a membership-based foundation organized to sustain the integrated Rule-Oriented Data System (iRODS) as free open source data management software.
by John Pletz, Crain's Chicago Business, 19 March 2015
By now, it’s no secret that Chicago and Illinois companies had a very good year in 2014 when it comes to venture funding.
More data continue to trickle in, this time from PricewaterhouseCoopers and the National Venture Capital Association.
Ericsson and Cleversafe Sign Global Partnership Agreement to Bring Next Generation Secure Cloud Storage Solution to Telecom Operators
Cleversafe, Wednesday, 04 March 2015
Cleversafe Inc., the web-scale storage market share leader, today announced its new partnership with Ericsson as the data storage platform provider
Intensity Therapeutics, Inc (pdf), 3 March 2015
Intensity Therapeutics, Inc. (private), developing novel cancer immunotherapy products, announced that President and CEO Lewis H. Bender will present at the 7th Annual Biotech Showcase & Investor Conference
Cleversafe, Wednesday, 05 January 2015
Cleversafe Inc., the industry-leading object-based storage provider, was named a Leader in the IDC MarketScape: Worldwide Object-Based Storage 2014 Vendor Assessment